WHO. Emergencies: International health regulations and emergency committees. https://web.archive.org/web/20210815072835/https://www.who.int/news-room/q-a-detail/emergencies-international-health-regulations-and-emergency-committees (2019).

Pandemic Prepardness Partnership. 100 Days Mission. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/992762/100_Days_Mission_to_respond_to_future_pandemic_threats__3_.pdf (2021).

WHO. Pathogens Prioritization: a Scientific Framework for Epidemic and Pandemic Research Preparedness. https://cdn.who.int/media/docs/default-source/consultation-rdb/prioritization-pathogens-v6final.pdf?sfvrsn=c98effa7_7&download=true (2024).

Bentley, E. M., Mather, S. T. & Temperton, N. J. The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination. Vaccine 33, 2955–2962 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Toon, K., Bentley, E. M. & Mattiuzzo, G. More than just gene therapy vectors: lentiviral vector pseudotypes for serological investigation. Viruses 13, 217 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whitt, M. A. Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365–374 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carnell, G. W., Ferrara, F., Grehan, K., Thompson, C. P. & Temperton, N. J. Pseudotype-based neutralization assays for influenza: a systematic analysis. Front. Immunol. 6, 161 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562–569 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sholukh, A. M. et al. Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays. J. Clin. Microbiol. 59, e0052721 (2021).

Article  PubMed  Google Scholar 

Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1885–1898 (2021).

Article  CAS  PubMed  Google Scholar 

Chu, L. et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat. Med. 28, 1042–1049 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steeds, K. et al. Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. Sci. Rep. 10, 14289 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bentley, E. M. et al. Cross-neutralisation of novel bombali virus by Ebola virus antibodies and convalescent plasma using an optimised pseudotype-based neutralisation assay. Trop. Med. Infect. Dis. vol. 6 at https://doi.org/10.3390/tropicalmed6030155 (2021).

Sampson, A. T. et al. Coronavirus pseudotypes for all circulating human coronaviruses for quantification of cross-neutralizing antibody responses. Viruses 13, 1579 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Enriquez, A. S. et al. Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies. Cell Rep. 39, 110841 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma, M. et al. Murine leukemia virus pseudotypes of La Crosse and Hantaan Bunyaviruses: a system for analysis of cell tropism. Virus Res. 64, 23–32 (1999).

Article  CAS  PubMed  Google Scholar 

Kuhn, J. H. et al. Promotion of order Bunyavirales to class Bunyaviricetes to accommodate a rapidly increasing number of related polyploviricotine viruses. J. Virol. 98, e0106924 (2024).

Article  PubMed  Google Scholar 

Boshra, H. An overview of the infectious cycle of bunyaviruses. Viruses 14, 2139 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jayakar, H. R., Jeetendra, E. & Whitt, M. A. Rhabdovirus assembly and budding. Virus Res. 106, 117–132 (2004).

Article  CAS  PubMed  Google Scholar 

Sandrin, V., Muriaux, D., Darlix, J.-L. & Cosset, F.-L. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J. Virol. 78, 7153–7164 (2004).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen, R., Huang, W. & Wang, Y. Pseudotyped virus for bandavirus. Adv. Exp. Med. Biol. 1407, 265–277 (2023).

Article  CAS  PubMed  Google Scholar 

Suda, Y. et al. Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system. Arch. Virol. 161, 1447–1454 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vasmehjani, A. A. et al. Efficient production of a lentiviral system for displaying Crimean-Congo hemorrhagic fever virus glycoproteins reveals a broad range of cellular susceptibility and neutralization ability. Arch. Virol. 165, 1109–1120 (2020).

Article  CAS  PubMed  Google Scholar 

Li, Y. et al. Packaging of Rift Valley fever virus pseudoviruses and establishment of a neutralization assay method. J. Vet. Sci. 19, 200–206 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Shtanko, O., Nikitina, R. A., Altuntas, C. Z., Chepurnov, A. A. & Davey, R. A. Crimean-Congo hemorrhagic fever virus entry into host cells occurs through the multivesicular body and requires ESCRT regulators. PLoS Pathog. 10, e1004390 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Rodriguez, S. E. et al. Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever. Sci. Rep. 9, 7755 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Antonelli, R. et al. A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison. F1000Research 13, 534 (2024).

CAS  PubMed  PubMed Central  Google Scholar 

WHO. Oropouche virus disease. https://www.who.int/news-room/fact-sheets/detail/oropouche-virus-disease (2024).

Ma, J. et al. In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus. Hum. Vaccin. Immunother. 15, 2286–2294 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Nichol, S. T. et al. The Bunyaviridae. in Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses (eds. Fauquet, C. M., Mayo, M. A., Maniloff, J., Desselberger, U. & Ball, L. A.) 695–716 (Elsevier, 2005).

Spik, K. et al. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24, 4657–4666 (2006).

Article  CAS  PubMed  Google Scholar 

Freitas, N. et al. The interplays between Crimean-Congo hemorrhagic fever virus (CCHFV) M segment-encoded accessory proteins and structural proteins promote virus assembly and infectivity. PLoS Pathog. 16, e1008850 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct. Target. Ther. 8, 149 (2023).

Article  PubMed  PubMed Central